Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma

Journal of Pathology

Volumn 203, Issue 2, 2004, Pages 638-644

  Kerr, Keith M ^a   Mackenzie, Suzi J ^a   Ramasami, Sharmini ^a   Murray, Graeme I ^a   Fyfe, Nicky ^a   Chapman, Andrea D ^a   Nicolson, Marianne C ^a   King, George ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

catenin; Adenocarcinoma; Adhesion molecules; Atypical adenomatous hyperplasia; Bronchioloalveolar carcinoma; E cadherin; Fhit; Lung cancer; MMP; Pre invasive lesions

Indexed keywords

BETA CATENIN; CD44V6 ANTIGEN; CELL ADHESION MOLECULE; FRAGILE HISTIDINE TRIAD PROTEIN; GELATINASE A; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UVOMORULIN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER SCREENING; CARCINOMA IN SITU; CELL CONTACT; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; MALIGNANT TRANSFORMATION; MIXED TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; TISSUE SECTION; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANTIGENS, CD44; BETA CATENIN; CADHERINS; CELL ADHESION MOLECULES; CYTOSKELETAL PROTEINS; EPITHELIUM; GLYCOPROTEINS; HUMANS; HYPERPLASIA; LUNG; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; PULMONARY ALVEOLI; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 2642570098     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1557     Document Type: Article

References (46)

1. Kitamura H, Kameda Y, Ito T, Hayashi H. Atypical adenomatous hyperplasia of the lung: implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol 1999; 111: 610-622.
2. Kerr KM. Pulmonary preinvasive neoplasia. J Clin Pathol 2001; 54: 257-271.
3. Mori M, Rao SK, Popper HH, Cagle PT, Fraire AE. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol 2001; 14: 72-84.
4. Travis WD, Colby TV, Corrin B, et al (eds). Histological Typing of Lung and Pleural Tumours. WHO International Histological Classification of Tumours. (3rd edn). Springer: Berlin, 1999; 29.
5. Shimosato Y, Kodama T, Kameya T. Morphogenesis of peripheral type adenocarcinoma of the lung. In Morphogenesis of lung cancer, Vol. 1, Shimosato Y, Melamed MR, Nettesheim P (eds). CRC press: Boca Raton, FL, 1982; 65-90.
6. Miller RR, Nelems B, Evans KG, Müller NL, Ostrow DN. Glandular neoplasia of the lung: a proposed analogy to colonic tumours. Cancer 1988; 61: 1009-1014.
7. Aoyagi Y, Yokose T, Minami Y, et al. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res 2001; 61: 7950-7954.
8. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol 1999; 17: 1618-1624.
9. Sozzi G, Tornielli S, Tagliabue E, et al. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997; 57: 5207-5212.
10. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD, Gazdar AF. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999; 18: 643-650.
11. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58: 5032-5037.
12. Marchetti A, Pellegrini S, Bertacca G, et al. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas: correlations with clinicopathological data and K-ras mutations. J Pathol 1998; 184: 240-246.
13. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M. E-cadherin mediated adhesion system in cancer cells. Cancer 1996; 77: 1605-1613.
14. Smith MEF, Pignatelli M. The molecular histology of neoplasia: the role of the cadherin/catenin complex. Histopathology 1997; 31: 107-111.
15. Rudzki Z, Jothy S. CD44 and the adhesion of neoplastic cells. J Clin Pathol: Mol Pathol 1997; 50: 57-71.
16. Bankfalvi A, Terpe H-J, Breukelmann D, et al. Immunophenotypic and prognostic analysis of E-cadherin and β-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999; 34: 25-34.
17. Ramasami S, Kerr KM, Chapman AD, King G, Cockburn JS, Jeffrey RR. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol 2000; 192: 427-432.
18. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastases. Eur J Cancer 2000; 36: 1621-1630.
19. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999; 189: 300-308.
20. Galateau-Salle FB, Luna RE, Horiba K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol 2000; 31: 296-305.
21. Kumaki F, Matsui K, Kawai T, Ozeki Y, Yu ZX, Ferrans VJ, Travis WD. Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol 2001; 159: 2125-2135.
22. Kitamura H, Osawa Y, Kawano N, et al. Basement membrane patterns, gelatinase A and tissue inhibitor of metalloproteinase-2 expressions, and stromal fibrosis during the development of peripheral lung adenocarcinoma. Hum Pathol 1999; 30: 331-338.
23. Kawano N, Osawa H, Ito T, et al. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum Pathol 1997; 28: 613-622.
24. Kerr KM. Adenomatous hyperplasia and the origin of peripheral adenocarcinoma of the lung. In Pathology of lung tumours, Corrin B (ed). Churchill Livingstone: Edinburgh, 1997; 119-134.
25. Kodama T, Biyajima S, Watanabe S, Shimosato Y. Morphometric study of adenocarcinomas and hyperplastic epithelial lesions in the peripheral lung. Am J Clin Pathol 1986; 85: 146-151.
26. Kitamura H, Kameda Y, Nakamura N, et at. Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma: analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am J Surg Pathol 1996; 20: 553-562.
27. Kerr KM. Atypical adenomatous hyperplasia versus nonmucinous bronchioloalveolar carcinoma: a spectrum of neoplasia in the lung periphery. Lung Cancer 2000; 29(S2): 94-95.
28. King G, Payne SNL, Walker F, Murray GI. A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J Pathol 1997; 183: 237-241.
29. Murray GI. Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998; 43: 791-797.
30. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60: 1949-1960.
31. Geradts J, Fong KM, Zimmerman PV, Minna JD. Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 2000; 82: 1191-1197.
32. Tseng JE, Kemp BL, Khuri FR, et al. Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 1999; 59: 4798-4803.
33. Garinis GA, Gorgoulis VG, Mariatos G, et al. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). J Pathol 2001; 193: 55-65.
34. Ho WL, Chang JW, Tseng RC, Chen JT, Chen CY, Jou YS, Wang YC. Loss of heterozygosity at loci of candidate tumour suppressor genes in microdissected primary non-small cell lung cancer. Cancer Detect Prev 2002; 26: 343-349.
35. Tomizawa Y, Nakajima T, Kohno T, Saito R, Yamaguchi N, Yokota J. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998; 58: 5478-5488.
36. Sozzi G, Sard L, De Gregorio L, et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 1997; 57: 2121-2123.
37. Fasano M, Sabatini MT, Wieczorek R, Sidhu G, Goswami S, Jagirdar J. CD44 and its spliced variant in lung tumours: a role in histogenesis? Cancer 1997; 80: 34-41.
38. Wimmel A, Kogan E, Ramaswamy A, Schuermann M. Variant expression of CD44 in preneoplastic lesions of the lung. Cancer 2001; 92: 1231-1236.
39. Ohori NP, Coppola D, Landreneau RJ. CD44v6 expression in primary bronchioloalveolar carcinoma and conventional pulmonary adenocarcinoma. Mod Pathol 1996; 9: 507-512.
40. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000; 12: 4789-4796.
41. Pirinen RT, Hirvikoski P, Johansson RT, Hollmen S. Kosma VM. Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J Clin Pathol 2001; 54: 391-395.
42. Lee YC, Wu CT, Chen CS, Hsu HH, Chang YL. The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated non-small cell lung cancers of 3cm or less in size. J Thorac Cardiovasc Surg 2002; 123: 502-507.
43. Bremnes RM, Veve R, Gabrielson E, et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002; 20: 2417-2428.
44. Bremnes RM, Veve R, Hirsch FR, Franklin WA. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis and prognosis. Lung Cancer 2002; 36: 115-124.
45. Kerr KM, Carey FA, King G, Lamb D. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression. J Pathol 1994; 174: 249-256.
46. Nakanishi K, Kawai T, Kumaki F, Hirot S, Mukai M, Ikeda E. Expression of human telomerase RNA product and telomerase reverse transcriptase mRNA in atypical adenomatous hyperplasia of the lung. Hum Pathol 2002; 33: 697-702.